Barclays’s Ironwood Pharmaceuticals IRWD Stock Holding History

Barclays’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-348,000	Closed	-$3.03M	–	5084
2024 Q1	$3.03M	Hold	348,000	–	–	﹤0.01%	2222
2023 Q4	$3.98M	Buy	348,000 +201,400	+137%	+$1.99M	﹤0.01%	2307
2023 Q3	$1.41M	Buy	+146,600	New	+$1.44M	﹤0.01%	2112
2019 Q1	–	Sell	-59,700	Closed	-$518K	–	7160
2018 Q4	$518K	Sell	59,700 -1,194	-2%	-$13.7K	﹤0.01%	3791
2018 Q3	$941K	Buy	60,894 +59,700	+5,000%	+$944K	﹤0.01%	3686
2018 Q2	$19K	Buy	+1,194	New	+$17.7K	﹤0.01%	6215
2018 Q1	–	Sell	-477,600	Closed	-$6M	–	7187
2017 Q4	$6M	Buy	+477,600	New	+$6.24M	﹤0.01%	1524
2016 Q2	–	Sell	-119,400	Closed	-$1M	–	6462
2016 Q1	$1M	Buy	+119,400	New	+$985K	﹤0.01%	2522
2014 Q3	–	Sell	-223,875	Closed	-$2.81M	–	7733
2014 Q2	$2.81M	Buy	+223,875	New	+$2.43M	﹤0.01%	2271

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's IRWD Position: Q2 2026 in Review

Barclays increased its Ironwood Pharmaceuticals (IRWD) stake by 11% in Q2 2026, buying an estimated $39.1K and bringing the position to 100,123 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #3322.

Barclays first reported a position in IRWD in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.32M in Q4 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Barclays held 100,123 shares of Ironwood Pharmaceuticals worth $422K as of Q2 2026.
Barclays bought 10,153 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $39.1K.
Ironwood Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3322 holding.
Barclays first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Barclays's Ironwood Pharmaceuticals position peaked at $6.32M in Q4 2023.
212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.